-
European Medicines Agency (EMA) Recommends Multaq Use Should Be Restricted For Safety Reasons
EMA Cites The Increased Risks Of Liver Injury, Lung Side Effects, And Cardiovascular Adverse Events (Posted by Tom Lamb at DrugInjuryWatch.com) In late September 2011 the European Medicines Agency (EMA) recommended that the use…
-
Many Patients Mistakenly Believe That A Prescription Drug Must Be Safe If FDA-Approved
Safety Problems With New Medications Often Appear Only After Approval And Widespread Use (Posted by Tom Lamb at DrugInjuryWatch.com) A medical journal article published in the September 12, 2011 edition of the Archives of…
-
Public Citizen Group Files FDA Petition To Fix Problems Exposed By Mensing Case Ruling
Generic Drug Companies Should Have To Update Side Effect Warnings Or Face Drug Injury Lawsuits (Posted by Tom Lamb at DrugInjuryWatch.com) On August 29, 2011 the consumer advocacy group Public Citizen took action in…
-
Multaq: August 2011 Update: Another Liver Failure Case Report Article In Medical Journal
New Sanofi "Dear Doctor" Letter: Label Change Regarding Heart-Related Side Effects Coming Soon (Posted by Tom Lamb at DrugInjuryWatch.com)This August 2011 update on Multaq (dronedarone) covers both liver injury and cardiovascular side effects. The medical…